【摘要】 目的探讨分析肺癌患者应用吉西他滨联合紫杉醇治疗的临床效果。方法选取2017年3月～2018年3月我院收治的92例肺癌患者作为研究对象,按照随机数字表法将其分为对照组（46例）和研究组（46例）。对照组患者采用吉西他滨联合顺铂方案治疗,研究组患者采用吉西他滨联合紫杉醇方案治疗。比较两组患者的治疗总有效率、肺功能影响以及不良反应发生情况。结果研究组患者的治疗总有效率高于对照组,差异有统计学意义（P<0.05）;治疗前,两组患者的第1秒呼气容积（FEV₁）、FEV₁百分比（FEV₁%）和FEV₁与肺活量（FVC）之间的比值（FEV₁/FVC）等肺功能指标水平比较,差异无统计学意义（P>0.05）,治疗后,两组患者的上述肺功能指标水平均高于本组治疗前,且研究组显著高于对照组,差异有统计学意义（P<0.05）。治疗后,研究组患者的肝功能损害、脱发、骨髓抑制、周围神经毒性等不良反应发生率及总发生率均显著低于对照组,差异有统计学意义（P<0.05）。结论肺癌患者应用吉西他滨联合紫杉醇治疗,治疗效果显著,对患者的肺功能影响较小,且不良反应发生率低,值得推广使用。更多还原

【Abstract】 Objective To investigate and analyze the clinical effect of Gemcitabine combined with Paclitaxel in patients with lung cancer. Methods Ninety-two patients with lung cancer admitted to our hospital from March 2017 to March2018 were selected as the study subjects. They were divided into control group（46 cases） and study group（46 cases）according to random number table method. The control group was treated with Gemcitabine combined with Cisplatin,and the study group was treated with Gemcitabine combined with Paclitaxel. The total effective rate, pulmonary function and adverse reactions were compared between the two groups. Results The total effective rate of the study group was higher than that of the control group, the difference was statistically significant（P<0.05）. There was no significant difference in lung function indexes such as forced expiratory volume in 1 s（FEV₁）, FEV₁ percentage（FEV₁%） and the ratio of FEV₁ to forced vital capacity（FVC）（FEV₁/FVC） between the two groups before treatment（P>0.05）. After treatment, the above lung function indexes of the two groups were higher than those before treatment, and the study group was significantly higher than the control group, with statistically significant difference（P<0.05）. After treatment, the incidence of liver function damage, alopecia, bone marrow suppression, peripheral neurotoxicity and the total incidence of adverse reaction in the study group were significantly lower than those in the control group（P<0.05）. Conclusion Gemcitabine combined with Paclitaxel in the treatment of lung cancer has significant therapeutic effect, less impact on pulmonary function, and low incidence of adverse reactions, which is worthy of promotion.更多还原